Patent · US Active

Cas9 mRNAs

US10927383B2 · kind B2 · utility

1Cited by

3References

10Claims

0Family size

Assignee

ethris GmbH · DE

Inventors

Manish Kumar Aneja · Munich, DE
Rebekka Kubisch-Dohmen · Munich, DE
Christian Plank · Wien, AT
Carsten Rudolph · Krailling, DE

Key dates

Filing date	Jun 30, 2017
Grant date	Feb 23, 2021
Priority date	—
Expiry date	Feb 11, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/20
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

In certain aspects, the disclosure relates to compositions comprising modified Cas9 polyribonucleotides and methods of use, as well as Cas9 polynucleotides and polyribonucleotides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.